Dr. Jack West asks the question of whether newer, more active ALK inhibitors such as alectinib should be used as first line therapy rather than for acquired resistance, including introducing...
show moreAuthor | cancerGRACE |
Website | - |
Tags |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company
Browse Spreaker Catalogue to discover great new content
Browse Spreaker Catalogue to discover great new content
It's so quiet here...
Time to discover new episodes!